CREST syndrome is a dubious disease in the field of autoimmune and rheumatic immunity, with clinical performance being complex and often involving multi-system congestion. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching domestic and foreign authoritative experts and teams to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in conditions.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of CREST syndrome. The platform serves the China International Medical Service System, a team of nationally authoritative experts in the field of autoimmune and rheumatic immunity, providing the following services to patients: Remote pre-diagnosis: by the team of experts to review the medical history, clarify diagnostic directions and provide medical advice: 1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.